Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of NAC in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to perform reproducible spirometry according to ATS criteria~* Clinical history consistent with moderate to severe asthma for 1 year or greater.~* Post-bronchodilator FEV1 \<90% of predicted~* Prescription and daily use of inhaled corticosteroid (ICS) equivalent to 240mcg of beclomethasone or greater and a second asthma controller therapy.~* CT mucus score \>3 (determined during the initial screening process, provided the prior two conditions are met)~* Written informed consent obtained from participant and ability for participant to comply with the requirements of the study.~Exclusion Criteria:~* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.~* History of intolerance to study medications.~* Current use of carbamazepine~* Angina which includes a treatment plan with PRN nitroglycerin or nitrites~* Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history~* Current participation in an investigational drug trial Concurrent Medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 20% n-acetylcystine (NAC) (Type: EXPERIMENTAL): NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
- 0.9% saline (Type: PLACEBO_COMPARATOR): Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.

Based on this trial design, predict the completion outcome and termination type (if applicable).